This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-2367v1 69/3/1000    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beevers, C. S. Articles by Huang, S. Search for Related Content PubMed PubMed Citation Articles by Beevers, C. S. Articles by Huang, S.

Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor Complex

¹ Department of Biochemistry and Molecular Biology and ² Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana; and ³ Department of Medicine, University of California, San Diego, La Jolla, California

Requests for reprints: Shile Huang, Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932. Phone: 318-675-7759; Fax: 318-675-5180; E-mail: shuan1{at}lsuhsc.edu.

Key Words: Curcumin • mammalian target of rapamycin • raptor • rictor • Akt

Curcumin (diferuloylmethane), a polyphenol natural product of the plant Curcuma longa, is undergoing early clinical trials as a novel anticancer agent. However, the anticancer mechanism of curcumin remains to be elucidated. Recently, we have shown that curcumin inhibits phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), two downstream effector molecules of the mammalian target of rapamycin complex 1 (mTORC1) in numerous cancer cell lines. This study was designed to elucidate the underlying mechanism. We observed that curcumin inhibited mTORC1 signaling not by inhibition of the upstream kinases, such as insulin-like growth factor 1 receptor (IGF-IR) and phosphoinositide-dependent kinase 1 (PDK1). Further, we found that curcumin inhibited mTORC1 signaling independently of protein phosphatase 2A (PP2A) or AMP-activated protein kinase AMPK-tuberous sclerosis complex (TSC). This is evidenced by the findings that curcumin was able to inhibit phosphorylation of S6K1 and 4E-BP1 in the cells pretreated with PP2A inhibitor (okadaic acid) or AMPK inhibitor (compound C), or in the cells expressing dominant-negative (dn) PP2A, shRNA to PP2A-A subunit, or dn-AMPK. Curcumin did not alter the TSC1/2 interaction. Knockout of TSC2 did not affect curcumin inhibition of mTOR signaling. Finally, we identified that curcumin was able to dissociate raptor from mTOR, leading to inhibition of mTORC1 activity. Therefore, our data indicate that curcumin may represent a new class of mTOR inhibitor. [Cancer Res 2009;69(3):1000–8]

This article has been cited by other articles:

				S. M. JOHNSON, P. GULHATI, I. ARRIETA, X. WANG, T. UCHIDA, T. GAO, and B. M. EVERS Curcumin Inhibits Proliferation of Colorectal Carcinoma by Modulating Akt/mTOR Signaling Anticancer Res, August 1, 2009; 29(8): 3185 - 3190. [Abstract] [Full Text] [PDF]

				D. A. Guertin and D. M. Sabatini The Pharmacology of mTOR Inhibition Sci. Signal., April 21, 2009; 2(67): pe24 - pe24. [Abstract] [Full Text] [PDF]